E. Negroni et al. from UPMC Université Paris reported in the July 21st online edition of J. Molecular Therapy their study results on comparing the myogenic potential of muscle-derived human CD133+ to muscle satellite cells in a mouse (Rag2-/-γC-/- C5-/-) muscle degeneration model. Following cryoinjury and intramuscular injection of the stem cells, the study data revealed that human muscle-derived CD133+ showed a greater capacity for muscle regeneration than human myoblasts. Immunohistochemistry analyses also showed an increase in the number of muscle fibers expressing human proteins when the damaged muscle was injected with CD133+ cells than with myoblasts. Additionally, the satellite cell niche appears to be more enriched by CD133+/CD34+ than by myoblasts. The authors concluded from their observations that "muscle-derived CD133+ cells could be an attractive candidate for cellular therapy."